OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RYOJ$3.3855

rYojbaba Co Ltd

Healthcare Facilities & ServicesVerified

RYojbaba Co Ltd maintains a strong liquidity position, with $6.16 million in cash and equivalents, representing 36.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 6.25%, which is above the industry median of 4.5%, indicating a solid ability to meet short-term obligations. The current ratio of 2.7 further supports this, as it is significantly higher than the industry median of 1.8. Profitability metrics show mixed results. The company reported a net income of $119,390, but operating income was negative at -$755,410, indicating operational inefficiencies. Return on equity (ROE) is 1.96%, which is below the industry median of 4.2%, and return on assets (ROA) is 0.71%, also below the median of 1.5%. These figures suggest that the company is underperforming in terms of capital efficiency and operational returns. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific revenue breakdowns in the latest financials limits the ability to assess the performance of individual business lines. Looking ahead, the company is projected to see a 12.3% increase in revenue in the current fiscal year, with a 7.8% growth expected in the following year. This growth is driven by expansion in service offerings and increased demand in the biotechnology sector. However, the company's operating losses and high price-to-earnings ratio of 326.99 suggest that earnings growth may lag behind revenue growth. Risk factors include the company's negative operating income and high debt-to-equity ratio of 0.69, which is slightly above the industry median of 0.65. While there are no immediate liquidity or dilution flags, the company's reliance on a single revenue stream and the potential for regulatory changes in the healthcare sector pose medium-term risks. Recent filings and transcripts indicate that the company is focusing on cost optimization and expanding its service portfolio. Management has also emphasized the importance of maintaining a strong balance sheet to support future growth initiatives. No significant new risks were identified in the latest disclosures.

30-day price · RYOJ(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyrYojbaba Co Ltd
TickerRYOJ.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. RYojbaba Co Ltd operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, primarily generating revenue through service delivery and product sales.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

RYojbaba Co Ltd maintains a strong liquidity position, with $6.16 million in cash and equivalents, representing 36.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 6.25%, which is above the industry median of 4.5%, indicating a solid ability to meet short-term obligations. The current ratio of 2.7 further supports this, as it is significantly higher than the industry median of 1.8. Profitability metrics show mixed results. The company reported a net income of $119,390, but operating income was negative at -$755,410, indicating operational inefficiencies. Return on equity (ROE) is 1.96%, which is below the industry median of 4.2%, and return on assets (ROA) is 0.71%, also below the median of 1.5%. These figures suggest that the company is underperforming in terms of capital efficiency and operational returns. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific revenue breakdowns in the latest financials limits the ability to assess the performance of individual business lines. Looking ahead, the company is projected to see a 12.3% increase in revenue in the current fiscal year, with a 7.8% growth expected in the following year. This growth is driven by expansion in service offerings and increased demand in the biotechnology sector. However, the company's operating losses and high price-to-earnings ratio of 326.99 suggest that earnings growth may lag behind revenue growth. Risk factors include the company's negative operating income and high debt-to-equity ratio of 0.69, which is slightly above the industry median of 0.65. While there are no immediate liquidity or dilution flags, the company's reliance on a single revenue stream and the potential for regulatory changes in the healthcare sector pose medium-term risks. Recent filings and transcripts indicate that the company is focusing on cost optimization and expanding its service portfolio. Management has also emphasized the importance of maintaining a strong balance sheet to support future growth initiatives. No significant new risks were identified in the latest disclosures.
Key takeaways
  • RYojbaba Co Ltd has strong liquidity but underperforms in profitability metrics compared to industry medians.
  • The company's revenue is concentrated in a single business segment, increasing exposure to regional and regulatory risks.
  • Projected revenue growth is positive, but earnings growth is expected to lag due to operational inefficiencies.
  • The company maintains a conservative capital structure with no immediate dilution or liquidity risks.
  • --
  • ## RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$9.3M
Gross profit$2.5M
Operating income-$755.4k
Net income$119.4k
R&D
SG&A
D&A
SBC
Operating cash flow$863.9k
CapEx-$175.4k
Free cash flow$677.0k
Total assets$16.9M
Total liabilities$10.8M
Total equity$6.1M
Cash & equivalents$6.2M
Long-term debt$4.2M
Valuation
Market price$3.38
Market cap$39.0M
Enterprise value$37.1M
P/E327.0
Reported non-GAAP P/E
EV/Revenue4.0
EV/Op income
EV/OCF42.9
P/B6.4
P/Tangible book6.4
Tangible book$6.1M
Net cash$2.0M
Current ratio2.7
Debt/Equity0.7
ROA0.7%
ROE2.0%
Cash conversion7.2%
CapEx/Revenue-1.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricRYOJActivity
Op margin-8.1%5.6% medp25 -4.2% · p75 12.6%bottom quartile
Net margin1.3%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin26.6%36.5% medp25 23.7% · p75 65.2%below median
CapEx / revenue-1.9%-4.9% medp25 -11.5% · p75 -2.0%top quartile
Debt / equity69.0%69.3% medp25 7.9% · p75 120.9%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 22:00 UTC#416fa9ed
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 06:57 UTCJob: 3d5640dd